...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of urology: official journal of the Japanese Urological Association >Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
【24h】

Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.

机译：血清人腺激肽释放酶2（hK2），用于区分前列腺癌的阶段和等级。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Human glandular kallikrein (hK2) has been shown to add important information regarding the early detection and staging of prostate cancer. Preliminary analysis pointed out that hK2 may discriminate between pT2 and pT3 tumors, and that hK2 may predict Gleason grade 4/5 cancer volume, better than prostate-specific antigen (PSA) or percent free PSA (%fPSA). We investigated the role of hK2 serum values for predicting pathological stage, grade and Gleason score. METHODS: Prostate-specific antigen, free PSA and hK2 were measured on 222 untreated prostate cancer patients who had received radical prostatectomy at the Charite Hospital, Berlin, Germany. Pathological work up revealed pT2-cancer in 111 patients and pT3-cancer in 111 patients. Grade 2 was found in 118 patients whereas grade 3 tumors were found in 104 patients. RESULTS: For pT2 and pT3 patients, the %fPSA (P=0.006), the ratios hK2/fPSA (P=0.08) and hK2xtPSA/fPSA (P=0.002) were all significant different whereas hK2 (P=0.143) and PSA (P=0.1) did not differ. Between grade 2 and grade 3 tumors, the hK2 alone (P=0.27), the %fPSA (P=0.13), the ratios hK2/fPSA (P=0.94) and hK2xtPSA/fPSA (P=0.12) did not separate, whereas PSA (P=0.039) showed a difference. The same relationships were found between the two groups in Gleason score<7 and >or=7. Neither the hK2 ratio, nor % fPSA was different. CONCLUSION: Human glandular kallikrein was not different between pT2 and pT3, nor between G2 versus G3 or Gleason scores<7 and >or=7 prostate cancer. Together with %fPSA, hK2 may only help to distinguish preoperatively between pT2 and pT3 prostate cancer but cannot add further information.
机译：背景：人类腺激肽释放酶（hK2）已被证明可以增加有关前列腺癌的早期检测和分期的重要信息。初步分析指出，hK2可以区分pT2和pT3肿瘤，并且hK2可以预测格里森4/5级癌症体积，优于前列腺特异性抗原（PSA）或游离PSA百分比（％fPSA）。我们调查了hK2血清值在预测病理分期，等级和格里森评分中的作用。方法：对德国柏林Charite医院接受根治性前列腺切除术的222名未经治疗的前列腺癌患者进行了前列腺特异性抗原，游离PSA和hK2的测定。病理检查显示111例患者患有pT2癌，111例患者患有pT3癌。 118例患者发现2级肿瘤，而104例患者发现3级肿瘤。结果：对于pT2和pT3患者，％fPSA（P = 0.006），hK2 / fPSA（P = 0.08）和hK2xtPSA / fPSA之比（P = 0.002）均具有显着差异，而hK2（P = 0.143）和PSA（ P = 0.1）没有差异。在2级和3级肿瘤之间，单独的hK2（P = 0.27），％fPSA（P = 0.13），hK2 / fPSA之比（P = 0.94）和hK2xtPSA / fPSA之比（P = 0.12）没有分开，而PSA（P = 0.039）显示出差异。两组之间在格里森评分<7和>或= 7中发现了相同的关系。 hK2比率和％fPSA都没有不同。结论：人腺激肽释放酶在pT2和pT3之间，G2与G3或Gleason评分<7和> = 7的前列腺癌之间没有差异。与％fPSA一起，hK2可能仅有助于在术前区分pT2和pT3前列腺癌，但无法添加更多信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号